Get started
Author

Samer A. Srour

Observed names: Samer A Srour, Samer Srour
ORCID: 0000-0002-6693-2025
Observed ORCIDs: 0000-0002-6693-2025, 0000-0002-5105-6691
OpenAlex ID: A5102949017
Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001–12
2016 · Samer A. Srour, Susan S. Devesa, et al. · British Journal of Haematology · 186
Four‐year follow‐up of a single arm, phase II clinical trial of ibrutinib with rituximab ( IR ) in patients with relapsed/refractory mantle cell lymphoma ( MCL )
2018 · Preetesh Jain, Jorge Romaguera, et al. · British Journal of Haematology · 65
Incidence of potentially human papillomavirus–related neoplasms in the United States, 1978 to 2007
2013 · George Kurdgelashvili, Graça M. Dores, et al. · Cancer · 54
Novel chemotherapy‐free combination regimen for ibrutinib‐resistant mantle cell lymphoma
2017 · Samer A. Srour, Hun J. Lee, et al. · British Journal of Haematology · 11
PDF
Patient-reported outcomes after CAR T-cell therapy in patients with hematological malignancies
2024 · Xin Shelley Wang, Samer A. Srour · Hematology · 3
PDF
P-1013. Incidence and Risk Factors for Fungal Infection after CD19-targeted Chimeric Antigen Receptor T cell Therapy for Non-Hodgkin Lymphoma
2025 · Charles Gaulin, Roy F Chemaly, et al. · Open Forum Infectious Diseases · 2
PDF
Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial
2026 · Samer A. Srour, Jad Chahoud, et al. · Journal of Clinical Oncology · 1
PA-434 Second Primary Malignancies After Autologous Transplantation for Multiple Myeloma in the Modern Treatment Era: Incidence, Risk Factors, and Prognostic Impact Using a Competing-Risk Approach
2026 · Damian Mikulski, Curtis Marcoux, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: CT-931: Preliminary Safety and Efficacy of Myeloablative Orca-Q in Patients With Haploidentical Donors
2026 · Amandeep Salhotra, Samer Srour, et al. · Clinical Lymphoma Myeloma & Leukemia
CT-931: Preliminary Safety and Efficacy of Myeloablative Orca-Q in Patients With Haploidentical Donors
2026 · Amandeep Salhotra, Samer Srour, et al. · Clinical Lymphoma Myeloma & Leukemia
CT-1718: Clinical Features and Outcomes of Transplant-Associated Thrombotic Microangiopathy Following Haploidentical Allogeneic Stem Cell Transplantation
2026 · Khalid G Alharbi, Samer A Srour · Clinical Lymphoma Myeloma & Leukemia
POSTER: CT-1718: Clinical Features and Outcomes of Transplant-Associated Thrombotic Microangiopathy Following Haploidentical Allogeneic Stem Cell Transplantation
2026 · Khalid G Alharbi, Samer A Srour · Clinical Lymphoma Myeloma & Leukemia
Phase I/II Trial of Evomela for Autologous Transplant in Myeloma: Schedule Optimization and Matched Comparison with MEL200
2026 · Qaiser Bashir, Peter F Thall, et al. · Blood Advances
D-VRD vs. D-KRD induction in transplant-eligible multiple myeloma: a real-world comparison
2026 · Oren Pasvolsky, Curtis Marcoux, et al. · Leukemia & lymphoma/Leukemia and lymphoma
Donor-specific transplant outcomes from BMT CTN 1702: a multicenter prospective biologic assignment trial
2026 · Asad Bashey, Brent Logan, et al. · Blood Advances
D-VRD induction and autologous transplant in patients ≥70 years
2026 · Oren Pasvolsky, Curtis Marcoux, et al. · Blood Cancer Journal
PDF
Daratumumab-Based Second Line Therapy Improves Outcomes After VRD Induction, Upfront Autologous Transplant, and Lenalidomide Maintenance
2026 · Oren Pasvolsky, Curtis Marcoux, et al. · Clinical Lymphoma Myeloma & Leukemia
Adverse Impact of MMF in AML/MDS Patients with High HCT-CI Receiving Matched Allogeneic Stem Cell Transplantation with PTCy-Based GvHD Prophylaxis
2026 · Jennifer Miatech, Rohtesh S. Mehta, et al. · Transplantation and Cellular Therapy
Evaluate the Safety and Efficacy of Short Versus Long Infusion Schedules of Evomela As Conditioning for Autologous Stem Cell Transplantation in Multiple Myeloma.Interpret Bayesian Modeling Results Assessing the Relationship between Melphalan Exposure (AUC) and Depth of Response or Progression-Free Survival.Identify Potential Pharmacokinetic (AUC) Targets That May Guide Individualized Evomela Dosing Strategies, Particularly for Patients with High-Risk Cytogenetics
2026 · Qaiser Bashir, Peter F. Thall, et al. · Transplantation and Cellular Therapy
A Phase 2 Trial of Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa, and Venetoclax (Cladillac) Conditioning for High-Risk MDS
2026 · Uday R. Popat, Chitra Hosing, et al. · Transplantation and Cellular Therapy
Peripheral Blood Stem Cell Collection for Patients with Multiple Myeloma Undergoing Autologous Transplant after Quadruplet Induction
2026 · Oren Pasvolsky, Denai R. Milton, et al. · Transplantation and Cellular Therapy
Impact of Renal Function on Autologous Stem Cell Transplantation (ASCT) Outcomes for AL Amyloidosis
2026 · Asad Jamal Rafique, Abdullah FaisalResearch DeenTrainee, et al. · Transplantation and Cellular Therapy
Daratumumab, Bortezomib, Lenalidomide and Dexamethasone, Upfront Autologous Transplant and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma
2026 · Oren Pasvolsky, Muhammad Bilal Abid, et al. · Transplantation and Cellular Therapy
Administration of Off-the-Shelf, Expanded, Most Closely HLA Matched, Third Party Viral Specific T cells for the Therapy of Adenovirus Related Disease in Adult Immunocompromised Patients
2026 · Mark Alexander Forsberg, Rebecca Pirtle, et al. · Transplantation and Cellular Therapy
Clinical Outcomes in Myelodysplastic Syndrome Patients Treated with Orca-T or Post-Transplant Cyclophosphamide Patients: A Registry-Based Comparison
2026 · Sagar S. Patel, Caspian Oliai, et al. · Transplantation and Cellular Therapy
Works count: 42
Citation count: 322
H-index: 4
I10-index: 4
Year
Topic
Type